BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer

Core Insights - BriaCell Therapeutics Corp. has received a positive recommendation from the independent Data Safety Monitoring Board (DSMB) for its pivotal Phase 3 study of Bria-IMT combined with immune checkpoint inhibitors in metastatic breast cancer [1][2][6] - This marks the third consecutive positive review from the DSMB, affirming the favorable safety profile of the treatment [2][3] - The study is being conducted under the Fast Track designation by the US FDA, indicating a significant unmet medical need in the patient population [2][6] Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care [1][3] - The company is currently advancing its Bria-IMT treatment, which has shown promising safety and tolerability in clinical trials [3]